Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03766581 · ClinicalTrials.gov registry record · Phase 2
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 2,366
- Enrollment target
NCT03766581 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 2,366 participants.
The verdict
NCT03766581, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2,366 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.
Interventions
- OTHER Placebo
- DRUG Aspirin
- DRUG Clopidogrel
- DRUG BMS-986177
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,366 participants |
| Start Date | 2019-01-27 |
| Est. Completion | 2022-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03766581
The ClinicalTrials.gov registry entry for NCT03766581 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2,366 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03766581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03766581 about?
NCT03766581 is a clinical study titled "A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel". The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.
What is the current status of trial NCT03766581?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,366 participants. The study started on 2019-01-27. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT03766581?
The interventions under investigation include: Placebo (OTHER), Aspirin (DRUG), Clopidogrel (DRUG), BMS-986177 (DRUG).
Who is sponsoring clinical trial NCT03766581?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.